Sydney Lupkin
Sydney Lupkin is the pharmaceuticals correspondent for NPR.
She was most recently a correspondent at Kaiser Health News, where she covered drug prices and specialized in data reporting for its enterprise team. She's reported on how tainted drugs can reach consumers, how companies take advantage of rare disease drug rules and how FDA-approved generics often don't make it to market. She's also tracked pharmaceutical dollars to patient advocacy groups and members of Congress. Her work has won the National Press Club's Joan M. Friedenberg Online Journalism Award, the National Institute for Health Care Management's Digital Media Award and a health reporting award from the Society for Advancing Business Editing and Writing.
Lupkin graduated from Boston University. She's also worked for ABC News, VICE News, MedPage Today and The Bay Citizen. Her internship and part-time work includes stints at ProPublica, The Boston Globe, The Boston Herald, The New England Center for Investigative Reporting and WCVB.
-
Children who need growth hormone to achieve their full stature are having trouble getting the medicine. A shortage has stretched months longer than expected and could last the rest of the year. -
Future access to the abortion drug mifepristone is called into question following competing rulings from federal judges in Texas and Washington State.
-
The FDA approved Narcan for sale without a prescription. The opioid overdose reversal drug would be available at pharmacies and convenience stores nationally, increasing access as opioid deaths climb.
-
In a long anticipated decision, the Food and Drug Administration approved an over-the-counter version of naloxone spray, a generic form of the opioid overdose treatment called Narcan.
-
Moderna is quadrupling the price of its COVID-19 vaccine when the U.S. government is no longer the exclusive buyer. Senators grilled the company's CEO on the hike and access for the uninsured.
-
Moderna said people without insurance will be able to get its COVID vaccine at no cost after the U.S. government bows out. But patients will have to use the company's cumbersome assistance program.
-
An insulin maker is cutting its prices. Eli Lilly, one of the three makers of insulin products in the United States, is also making other moves toward affordability for people with diabetes.
-
A federal judge is set to rule in a case challenging the FDA's approval of an abortion pill decades ago. Siding with the anti-abortion group may have ripple effects on drug approvals as we know them.
-
A shortage of both generic and brand-name Adderall began in October. That's left many ADHD patients without their needed medication.
-
When a pharmaceutical drug has been on the market a while, it's supposed to go generic and the price is supposed to go down. For blockbuster arthritis drug Humira, that hasn't happened — until now.
